Objective. Systemic-onset juvenile idiopathic arthritis (JIA) is speculated to follow a biphasic course, with an initial systemic disease phase driven by innate immune mechanisms and interleukin-1b (IL-1b) as a key cytokine and a second chronic arthritic phase that may be dominated by adaptive immunity and cytokines such as IL-17A. Although a recent mouse model points to a critical role of IL-17-expressing g/d T cells in disease pathology, in humans, both the prevalence of IL-17 and the role of IL-17-producing cells are still unclear.
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Dirk Holzinger, 1 Ndate Fall, 2 Alexei A. Grom, 2 Niklas Gruen, 1 and Dirk Foell 1 Objective. Systemic-onset juvenile idiopathic arthritis (JIA) is speculated to follow a biphasic course, with an initial systemic disease phase driven by innate immune mechanisms and interleukin-1b (IL-1b) as a key cytokine and a second chronic arthritic phase that may be dominated by adaptive immunity and cytokines such as IL-17A. Although a recent mouse model points to a critical role of IL-17-expressing g/d T cells in disease pathology, in humans, both the prevalence of IL-17 and the role of IL-17-producing cells are still unclear.
Methods. Serum samples from systemic JIA patients and healthy pediatric controls were analyzed for the levels of IL-17A and related cytokines. Whole blood samples were studied for cellular expression of IL-17 and interferon-g (IFNg). CD41 and g/d T cells isolated from the patients and controls were assayed for cytokine secretion in different culture systems.
Results. IL-17A was prevalent in sera from patients with active systemic JIA, while both ex vivo and in vitro experiments revealed that g/d T cells overexpressed this cytokine. This was not seen with CD41 T cells, which expressed strikingly low levels of IFNg. Therapeutic IL-1 blockade was associated with partial normalization of both cytokine expression phenotypes. Furthermore, culturing healthy donor g/d T cells in serum from systemic JIA patients or in medium spiked with IL-1b, IL-18, and S100A12 induced IL-17 overexpression at levels similar to those observed in the patients' cells.
Conclusion. A systemic JIA cytokine environment may prime g/d T cells in particular for IL-17A overexpression. Thus, our observations in systemic JIA patients strongly support a pathophysiologic role of these cells, as proposed by the recent murine model. Systemic juvenile idiopathic arthritis (JIA) is a unique form of childhood arthritis with features of an autoinflammatory disease. Due to complications, such as macrophage activation syndrome (MAS) and destructive arthritis, systemic JIA is associated with higher morbidity compared to other JIA subtypes (1) .
At disease onset, systemic JIA is characterized by quotidian fever, polyserositis, evanescent rash, and substantial systemic inflammation (2, 3) . High levels of interleukin-6 (IL-6), IL-18, as well as S100A8/A9 and S100A12 are detectable in serum (4), while IL-1b in particular is critically involved in initially driving inflammation. This became evident from remarkably improved disease outcome seen upon therapeutic IL-1 blockade (5), which seems particularly effective when initiated as first-line therapy (6, 7) . In contrast, children with established polyarthritis have been reported to have a worse clinical response to recombinant IL-1 receptor antagonist (IL-1Ra; anakinra) treatment (8, 9) . Current clinical trial results suggest that these patients benefit from therapeutic IL-6 receptor (IL-6R) blockade (tocilizumab) instead (10) .
It is speculated that systemic JIA may follow a biphasic clinical course, with innate immune mechanisms primarily involved in the pathology of the systemic disease stage and adaptive immune mechanisms significantly contributing to the later, chronic arthritic phenotype (11) . In fact, the HLA-DRB1*11 class II molecule has been found to be associated with susceptibility to systemic JIA, although the exact mechanistic implication in the disease pathology is still unclear (12) .
To date, the only data supporting involvement of adaptive immunity in systemic JIA are related to T cells. These describe skewed patterns of Th1/Th2 cells as well as increased numbers of interleukin-17 (IL-17)-producing Th17 cells (13, 14) . IL-17 can drive chronic arthritis (15) and can be produced by either Th17 (16) , g/d (g/d T17) (17) , CD81 (18) , or natural killer (NK) (19) T cells. It has been proposed that in systemic JIA, high levels of IL-1b and IL-6 during the systemic phase may favor induction of such cells (11) . Interestingly, g/d T cells in particular have been critically implicated in the disease pathology of a recently introduced systemic JIA mouse model in which a hyperinflammatory phenotype is induced upon administration of Freund's complete adjuvant (20) . This model is reported to resemble systemic JIA in a number of clinical, biologic, and histopathologic features. Phenotype induction required an IFNg l 8 w or IFNg -/-background. In these animals, g/d T cell numbers in draining lymph nodes as well as their IL-17 expression were strongly increased (20) .
The role of IL-17 in systemic JIA patients is currently unclear. Data on IL-17 serum levels are inconsistent (8, 21) . It has been speculated that Th17 cells contribute to local IL-17 expression (11, 13) , while low frequencies of peripheral g/d T cells in particular have been reported, as these cells are thought to predominantly reside at sites of inflammation (22) . In this study, we found markedly increased IL-17A serum levels in patients with active systemic JIA, whereas both ex vivo and particularly in vitro g/d T cells revealed significant IL-17A overexpression.
PATIENTS AND METHODS
Study subjects and samples. Serum samples from patients with active and inactive systemic JIA (n 5 12) were collected (between December 2011 and June 2014) at Cincinnati Children's Hospital Medical Center for analysis of cytokines. Samples from healthy pediatric control subjects (n 5 10) were collected at St. Franziskus Hospital in Munster, Germany. All samples were stored at 2208C until analyzed. For flow cytometry studies, fresh heparinized peripheral blood was obtained from 12 systemic JIA patients and 10 familial Mediterranean fever (FMF) patients (autoinflammatory disease controls) collected at the University Children's Hospital in Munster, Germany (between August 2014 and June 2015). Samples from 13 healthy pediatric donors were obtained from St. Franziskus Hospital (Table 1) . For in vitro studies, peripheral blood mononuclear cells (PBMCs) from systemic JIA patients (n 5 5) as well as healthy controls (n 5 5) were prepared and stored at 21508C until analyzed.
Inactive disease was defined as the absence of fever (in systemic JIA and FMF patients), rash, and arthritis (in systemic JIA patients) and a C-reactive protein level and/or an erythrocyte sedimentation rate in the range of normal (in systemic JIA [23] and FMF [24] patients).
All study subjects or their parents provided written informed consent. The study was approved by the respective local ethics committees.
Bead array assays. Serum cytokines (see below) were measured using a multiplex immunoassay as previously described (25) . Serum S100A12 was detected by a combination of in-house monoclonal anti-S100A12 antibodies translated to the MagPlex microsphere platform (Luminex). Data acquisition was performed on a MagPix instrument (Merck Millipore) using xPONENT v4.2 software (Luminex). Data were analyzed using ProcartaPlex Analyst software (v1.0; eBioscience). Cell culture supernatant cytokines were quantified using ProcartaPlex panels (eBioscience) according to the manufacturer's instructions.
Cell stimulation and flow cytometry stainings. Samples of whole heparinized peripheral blood (100 ml) were surfacestained for flow cytometric analysis of the expression of CD3 (clone OKT3), CD4 (RPA-T4), and g/d T cell receptor (TCR; B1) (all from BioLegend). Respective antibodies were used in excess. One triplicate set (100 ml each) was stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of brefeldin A and monensin (cell stimulation cocktail including protein transport inhibitor; eBioscience). A second triplicate set was left untreated. After stimulation (4 hours at 378C in an atmosphere of 5% CO 2 ), erythrocytes were lysed, and the remaining cells were fixed (1-step fix/lyse solution; eBioscience). Cells were permeabilized (FoxP3/transcription factor staining buffer set; eBioscience) and stained for intracellular IL-17A (BL168; BioLegend) or interferon-g (IFNg) (4S.B3; eBioscience). All antibodies were added at 5 ml/sample. Cells were analyzed by flow cytometry (FACSCanto flow cytometer; BD Biosciences). Collected data were analyzed using FlowJo software (v10.0.8). To evaluate cytokine expression, median fluorescence intensities (MFIs) were calculated. The flow cytometer was calibrated daily using CS&T beads (BD Biosciences) and the preset photomultiplier values were not changed throughout the whole study.
In vitro T cell stimulation. CD31g/dTCR1 and CD41 T cells were isolated from PBMCs obtained from patients with systemic JIA and healthy controls with the use of human g/d or CD41 T cell isolation kits (StemCell Technologies). Monocytes were isolated from PBMCs prepared from a single healthy donor (human monocyte isolation kit; StemCell Technologies). T cells (2 3 10 4 ) were cocultured with monocytes (4 3 10 4 ) in RPMI 1640 medium (Merck Millipore) or in medium supplemented with 100 pg/ml of lipopolysaccharide (LPS; Sigma-Aldrich) or recombinant LPS-free S100A12 (produced in-house). Additionally, healthy donor g/d T cells were either cocultured with monocytes in fetal calf serum-free RPMI 1640 medium supplemented with the endogenous g/d TCR ligand isopentenyl pyrophosphate (IPP; 10 mg/ml) (Sigma-Aldrich), IL-2 (100 units/ml; PeproTech), and 20% (volume/volume) systemic JIA patient or healthy pediatric control sera, or cultured with colchicine. † These 12 patients with systemic juvenile idiopathic arthritis (JIA) provided samples during both active and inactive disease. ‡ Three of the 12 patients with systemic JIA provided samples during both active and inactive disease. Sampling time points were at least 10 weeks apart. § Patients who had no joints with active disease were categorized as active, systemic disease status. Patients who had joints with active disease but no fever/rash were categorized as active, arthritic disease status.
monocytes in S100A12 (20 mg/ml) and medium treated with recombinant cytokine (10 ng/ml of IL-18, 10 ng/ml of IL-1b, or IL-18 plus IL-1b). Where indicated, cultures were further treated with 1 mg/ml of anti-IL-6 receptor (anti-IL-6R; tocilizumab; Hoffmann-La Roche), 1 mg/ml of anti-IL-1b (canakinumab; Novartis), or 10 mg/ml of anti-Toll-like receptor 4 (anti-TLR-4; clone W7C11; InvivoGen) antibodies.
On day 0 and day 3, cultures were supplemented with 100 units/ml of recombinant IL-2. An additional set of stimulations was supplemented with 1 mg/ml of canakinumab on day 0. On day 6, g/d T cells were restimulated with 10 mg/ml of IPP (24 hours at 378C in an atmosphere of 5% CO 2 ). CD41 T cells were superstimulated with PMA/ionomycin (6 hours at 378C in an atmosphere of 5% CO 2 ). Supernatants were harvested, cleared from remnant cells, and analyzed for cytokine expression using bead array assays as described above.
Statistical analysis. Data were analyzed with GraphPad Prism software (version 6.0 for Mac OS X). Depending on data distribution, multiple group comparisons were performed using one-way analysis of variance or the Kruskal-Wallis test followed by Bonferroni's or Dunn's post test, respectively. Where indicated, group-to-group comparisons were performed using Mann-Whitney U test or Wilcoxon's signed rank test. P values less than or equal to 0.05 were considered statistically significant.
RESULTS
Overexpression of serum IL-17A in patients with active systemic JIA. Serum samples were analyzed for levels of the inflammatory disease activity biomarker S100A12 as well as cytokine and chemokine expression associated with the generation and propagation of IL-17A-expressing T cells (IL-1b, IL-6, IL-17A, and IL-23) as well as IFNg expression and signaling (IL-18, IFNg, CXCL10, and CXCL9) ( Figure 1) .
Levels of IL-6 were significantly elevated in sera from systemic JIA patients (P 5 0.014) and were further increased in samples from patients with active disease (P 5 0.0002 versus healthy controls and P , 0.0001 versus patients with inactive disease). Levels of IL-17, IL-18, and S100A12 changed in parallel with systemic JIA disease activity as defined by clinical parameters (Table  1 ) and were significantly elevated in patients with especially active systemic JIA as compared to healthy children or patients with inactive systemic JIA. Serum levels of IL-1b, IFNg, and CXCL10 tended to follow disease activity, albeit below the significance level, while serum concentrations of IL-23 and CXCL9 remained at or even below those in healthy controls.
Reduced expression of IFNg in CD41 T cells from patients with systemic JIA. CD41 T cells in freshly drawn whole blood samples were analyzed for IFNg and IL-17A expression following PMA/ionomycin stimulation ( Figure 2A ). In our mixed cohort of systemic JIA patients (Table 1) , the proportions of CD41 T cells among total lymphocytes were significantly increased compared to healthy controls, both in PMA/ionomycin- Figure 1 . Serum cytokine and chemokine levels in systemic juvenile idiopathic arthritis (JIA). Interleukin-1b (IL-1b), IL-6, IL-17A, IL-18, IL-23, S100A12, interferon-g-(IFNg), CXCL10 (IFNg-inducible 10-kd protein), and CXCL9 (monokine induced by IFNg [MIG] ) in the sera of systemic JIA (sJIA; n 5 12) patients and healthy controls (HC; n 5 10) was detected by bead array assay. Except for CXCL9, results are presented as raw data on a log-scale y-axis. Results are shown for the entire group of systemic JIA patients and for the subgroups with active disease (AD; n 5 12) and inactive disease (ID; n 5 12) (see Table 1 for details). Bars show the mean 6 SEM. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001; **** 5 P , 0.0001, by Kruskal-Wallis test followed by Dunn's multiple comparison test. stimulated (P 5 0.0007) ( Figure 2B ) and untreated (data not shown) samples. Circulating CD41 T cell frequencies in FMF patients (both active and inactive disease) (Table  1) , who were included as an autoinflammatory disease control group, were similarly increased (P 5 0.0014) ( Figure  2B ). Although increased proportions of CD41 T cells were observed in systemic JIA patients with both active and inactive disease, this was particularly evident in patients with inactive disease (P 5 0.0003).
Following PMA/ionomycin stimulation, proportions of CD41 T cells positive for IFNg (CD31CD41IFNg1) in whole blood from systemic JIA patients were significantly Table 1 for details). Bars show the mean 6 SEM. * 5 P , 0.05; *** 5 P , 0.001, by Kruskal-Wallis test followed by Dunn's multiple comparison test. In contrast to IFNg, we observed no apparent differences in intracellular IL-17A expression levels among CD41 T cells based on the MFI values ( Figure 2D, right) .
Increased expression of IL-17A in g/d T cells from patients with systemic JIA. We also analyzed CD31 g/dTCR1 cells in whole blood for PMA/ionomycininduced IFNg and IL-17A expression ( Figure 3A ). In contrast to the elevated CD41 T cell percentages observed in systemic JIA patients, the proportions of CD31 T cells expressing g/d TCR (g/d T cells) were nonsignificantly reduced in systemic JIA patients compared to healthy controls (P 5 0.3) ( Figure 3B ) as well as to FMF patients (P 5 0.7) in both PMA/ionomycin-stimulated and untreated samples (data not shown). This reduction was not affected by the activity of the underlying systemic JIA. Similarly, frequencies of IFNg1g/d T cells were nonsignificantly reduced in whole blood from systemic JIA patients compared to healthy controls as well as to FMF patients ( Figure 3C, left) , while the intracellular IFNg expression levels tended to be increased, except for those in samples obtained during active systemic JIA (Figure 3D, left) .
Despite their apparent reduced frequency in the circulation, systemic JIA g/d T cells revealed significantly increased intracellular IL-17A expression compared to healthy control cells (P 5 0.023) ( Figure 3D, right) . This seemed not to be due to an expansion of CD31 g/dTCR1IL-17A1 cells or IL-17/IFNg double-expressing g/d T cells ( Figure 3C , middle and right). Increased g/d T cell expression of IL-17A in systemic JIA patients was particularly evident in cells obtained during inactive disease (P 5 0.012 versus healthy controls and P 5 0.06 versus FMF patients), while cytokine expression levels in patients with active JIA were still elevated compared to both healthy controls and FMF patients, albeit this was below statistical significance level ( Figure 3D, right) .
Normalization of aberrant expression of IFNg and IL-17A phenotypes during IL-1 blockade. IL-1b antagonists have been demonstrated to result in remarkably improved disease outcome in systemic JIA. The majority of patient samples analyzed in flow cytometry (n 5 11) were obtained during anti-IL-1 therapy with either anakinra or canakinumab ( Table 1 ). All patients had received corticosteroids prior to initiating IL-1 blockade. IL-1 blockade was introduced in the context of systemic JIA refractory to or dependent on corticosteroid therapy (26) . During the time of sampling, some patients were treated with just IL-1 antagonists, while others received additional corticosteroid or conventional diseasemodifying antirheumatic drug treatment (Table 1) .
In this mixed systemic JIA cohort, we noted that g/d T cells in whole blood obtained during therapeutic IL-1 blockade revealed lower intracellular IL-17A expression compared to samples from patients receiving other treatments, including IL-6 blockade (P 5 0.011 versus healthy controls) ( Figure 3E ). This seemed to be unaffected by the underlying disease activity as well as by the proportions of CD31g/dTCR1IL-17A1 or IL-17/IFNg doubleexpressing g/d T cells (see Supplementary Figure 1E (Table 1) . Moreover, we noted that the levels of intracellular IFNg expression normalized over the course of therapeutic IL-1 blockade, while cytokine expression in cells from patients receiving other treatments remained significantly decreased compared to healthy controls (P 5 0.013) (Supplementary Figure 1C,  right) .
Expression of IL-17A and IFNg in culture supernatants of T cells from patients with systemic JIA. To verify the observed cytokine expression phenotypes based on MFI data, we examined IL-17A and IFNg expression at the level of the secreted protein rather than analyzing transcription signatures in these partly very scarce cell populations. CD31g/dTCR1 cells were isolated from systemic JIA patients or healthy controls (n 5 5 per group) and cultured at a 1:2 ratio with heterologous monocytes isolated from a single healthy donor, in medium supplemented with IPP and IL-2 as well as either LPS (100 pg/ml) or S100A12 (20 mg/ml), where indicated ( Figures 4A and B) . These experiments required coculture with viable monocytes since stimulations of g/d T cells alone or in coculture with fixed monocytes did not result in cytokine expression. Table 1 for details). Data in E are shown for treatment at the time of blood sampling (n 5 3 with active disease and n 5 8 with inactive disease for other treatment; n 5 2 each with active and inactive disease). Bars show the mean 6 SEM. * 5 P , 0.05 by Kruskal-Wallis test followed by Dunn's multiple comparison test.
g/d T CELL OVEREXPRESSION OF IL-17 IN SYSTEMIC JIA
Upon stimulation with the common g/d TCR ligand IPP, only a minor increase in basal IL-17A expression by g/d T cells from systemic JIA patients as compared to controls was observed ( Figure 4A ). However, when the TLR-4 ligand LPS or S100A12 was added to the culture, IL-17A expression by g/d T cells from systemic JIA patients was significantly increased compared to controls (P 5 0.007 for LPS and P 5 0.008 for S100A12). This enhanced g/d T cell IL-17A secretion was strongly reduced following IL-1b neutralization (P 5 0.01 for LPS and P 5 0.06 for S100A12) ( Figure 4A ).
While we did not observe a pronounced IL-17A expression phenotype without additional TLR-4 stimulation, IFNg secretion by systemic JIA g/d T cells was significantly reduced following IPP stimulation alone (P 5 0.008 versus healthy controls) and was not affected by IL-1b neutralization (P 5 0.01 versus healthy controls) ( Figure 4B ). We observed no significant changes in g/d T cell IFNg expression between Figure 4 . Cytokine expression by isolated T cells from patients with systemic juvenile idiopathic arthritis (JIA). CD31g/dTCR1 cells (A and B) and CD31CD41 cells (C and D) were isolated from peripheral blood mononuclear cells (PBMCs) from systemic JIA (sJIA) patients and healthy controls (HC; n 5 5 per group) (see Table 1 for details) and cultured at a 1:2 ratio with heterologous monocytes from a single healthy donor. A and B, Cells were cultured for 6 days with 10 mg/ml of isopentenyl pyrophosphate (IPP) in medium alone or medium supplemented with 100 pg/ml of lipopolysaccharide (LPS) or 20 mg/ml of S100A12. Interleukin-2 (IL-2; 30 units/ml) was added on day 0 and day 3. In a parallel set of stimulations, cultures were supplemented with canakinumab (1 mg/ml) on day 0. On day 6, cells were restimulated with IPP, and the secretion of IL-17A (A) and interferon-g (IFNg) (B) into culture supernatants was quantified by bead array assay. C and D, CD41 T cells from the same JIA patients and controls were cultured under similar conditions as above, except for the addition of IPP. On day 6, cells were superstimulated with phorbol 12-myristate 13-acetate/ionomycin for 6 hours, and the release of IL-17A (C) and IFNg (D) into culture supernatants was quantified by bead array assay. Bars show the mean 6 SEM. Values in individual subjects are shown as scattered dot blots. * 5 P , 0.05; ** 5 P , 0.01, by Mann-Whitney U test for patients versus controls and by Wilcoxon's signed rank test for the impact of anti-IL-1 blockade. patients and controls following additional TLR-4 stimulation ( Figure 4B) .
In similar stimulation experiments using CD41 T cells, we observed no differences in IL-17A expression between patients and controls ( Figure 4C ) following 6 days of coculture in the presence of IL-2, LPS (100 pg/ml), or S100A12 (20 mg/ml) and subsequent PMA/ionomycin superstimulation. Instead, when analyzing these cells for the release of IFNg, this was significantly reduced in cells from the patients under all stimulation conditions tested ( Figure 4D ). This was not affected by IL-1b blockade except for stimulations with S100A12.
When analyzing cell culture supernatants for levels of IL-1b, IL-6, and IL-23, we observed no differences in their concentrations between cultures of g/d TCR1 cells ( Supplementary Figures 2A-C Figures 2D-F ) from patients and healthy controls. No free IL-1b was detectable in supernatants of cultures treated with canakinumab ( Supplementary Figures 2A and D) .
Promotion of g/d T cell IL-17A expression by a systemic JIA serum environment. Systemic JIA serum contains elevated levels of IL-1 as well as high concentrations Figure 5 . Promotion of g/d T cell interleukin-17A (IL-17A) expression by a systemic juvenile arthritis (JIA) serum factor environment. A, Healthy donor g/d T cells and monocytes together with isopentenyl pyrophosphate (IPP) and IL-2 were cultured in medium supplemented with 20% serum from systemic (fever/rash, but no active joints) or arthritis-prone systemic (no fever/rash but active joints) JIA patients as well as JIA patients in remission (no clinical symptoms) and pediatric healthy control donors (n 5 5 per group) (see Table 1 for details). Where indicated, cultures were treated with anti-IL-1 (canakinumab 1 mg/ml), anti-IL-6 receptor (IL-6R; tocilizumab 1 mg/ml), or anti-Toll-like receptor 4 (anti-TLR-4; 10 mg/ml) antibody. Background cytokine levels were determined in medium supplemented with serum alone (no cells). Following IPP restimulation on day 6, levels of IL-17A, IL-1b, IL-6, IL-18, IL-23, and S100A12 in culture supernatants were quantified by bead array assay. B, Healthy donor g/d T cells (n 5 6) together with monocytes, IPP, and IL-2 were left unstimulated or were stimulated with S100A12 (20 mg/ml), recombinant IL-18 (10 ng/ml), IL-1b (10 ng/ml), or IL-18 plus IL-1b where indicated. Cocultures stimulated with S100A12 plus IL-18 plus IL1b were treated with either anti-IL-6R (tocilizumab 1 mg/ml) or IL-1b (canakinumab 1 mg/ml) blockade. Following IPP restimulation on day 6, levels of IL-17A in culture supernatants were quantified by bead array assay. (For levels of IL-1b, IL-6, and IL-23, see Supplementary Figure 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40099/abstract.) Solid bars represent stimulations with S100A12; open bars indicate no S100A12 stimulation. Bars show the mean 6 SEM. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.001; **** 5 P , 0.0001, by Kruskal-Wallis test followed by Dunn's multiple comparison test. Figure 5A ). Although the observed levels of IL-17 were generally low ( Figure 5A ), they revealed significant increases compared to 20% systemic JIA serum-supplemented medium without cultured cells. Blockade of IL-1b or TLR-4 reduced g/d T cell IL-17 expression induced by either systemic (fever/ rash, but no active joints) or arthritis-prone systemic (no fever/rash but active joints) JIA patient serumsupplemented medium, while this appeared to be less pronounced following IL-6R blockade.
As observed with IL-17A, compared to serum in medium (no cells) as well as cultures additionally treated with blocking agents, we also detected increased levels of free IL-1b in cultures with systemic or arthritis-prone systemic JIA serum-supplemented medium. Similarly, IL-6, IL-18, and S100A12 were found to be strongly increased in systemic JIA sera-treated cultures, regardless of cytokine (IL-1b, IL-6) or TLR-4 blockade. High levels of both IL-18 and S100A12 were detectable even in 20% systemic JIA serum-supplemented medium without cells. No increase in IL-23 was measured in any systemic JIA serum culture.
As immunomodulatory medication in both patient serum and cells may eventually affect experimental outcome, we continued by testing IL-17A expression in healthy donor g/d T cells upon stimulation with recombinant IL-1b, IL-18, and S100A12 ( Figure 5B ). These experiments revealed that the addition of IL1b as well as a 1:1 combination of IL-18 plus IL-1b gradually increased the release of IL-17A from g/d T cells. This was strongly enhanced by further stimulation of cocultures with S100A12 in addition to the IL-1b or IL-1b plus IL-18. The latter combination of stimulants resulted in IL-17A expression levels comparable to those previously observed with cultured systemic JIA g/d T cells ( Figure 4A Figures 4C and D) .
The addition of IL-1b as well as IL-1b plus IL-18 gradually increased IL-6 expression in cocultures (Supplementary Figure 3B ). Yet, this was most pronounced by stimulation with S100A12, either alone or combined with recombinant cytokines. In contrast to IL-1b and IL-6, IL-23 expression was low and appeared to be unaffected (P not significant) by the various stimulations (Supplementary Figure 3C) .
DISCUSSION
In this study, we report ex vivo and in vitro data demonstrating a pronounced overexpression of IL-17A by g/d T cells from patients with systemic JIA, which seemed to occur in an environment of decreased T cell IFNg expression. This cytokine expression pattern appeared to be partly sensitive to anti-IL-1 treatment. Thus, our patient data are strikingly similar to key pathomechanistic findings reported in a recent systemic JIA mouse model, which revealed the most pronounced clinical phenotype on an IFNg -/-background and appeared to be critically dependent on IL-17 overexpression by g/d T cells (20) .
Increased IL-17A levels in systemic JIA were already apparent at the serum level. While current published data on this feature are inconsistent (8, 21) , we observed IL-17A serum concentrations in systemic JIA to be significantly increased over those in healthy controls when stratifying patients for underlying disease activity (Figure 1 ). This observation, together with the reported findings in the systemic JIA mouse model, provided the rationale for our studies on systemic JIA patients' T cells. Although the relatively small patient cohort studied may pose a limitation, for the ex vivo T cell phenotyping as well as in vitro, we focused on well-characterized patients with both systemic and arthritis-prone disease (Table 1) available in our center.
Ex vivo T cell phenotyping indicated that systemic JIA g/d T cells, but not CD41 T cells, overexpress IL-17A. Although we observed partly elevated Th17 cell (CD31 CD41IL-17A1) frequencies in whole blood from systemic JIA patients ( Figure 2D ), which is consistent with previously published data (13), these cells did not express IL-17A at higher intracellular levels than did Th17 cells from healthy controls or FMF autoinflammatory disease control patients. Similarly, IL-17 expression from isolated systemic JIA CD41 T cells was not elevated compared to controls ( Figure 4B) .
In contrast to elevated Th17 cell frequencies, g/d T cell overexpression of IL-17A in whole blood from patients with systemic JIA did not seem to be due to an expansion of CD31g/dTCR1IL-17A1 (g/d T17) cells ( Figure 3D ). Importantly, g/d T cell overexpression of IL-17 in systemic JIA was reproduced at the level of isolated cells. Yet, this did not readily occur upon stimulation with IPP alone, although together with IL-2, this was shown to expand g/d T cells in systemic JIA synovial fluid (27) , but required costimulation with TLR-4 ligands such as LPS or S100A12, providing the cytokine environment (IL-1b, IL-6, IL-23) (Supplementary Figure 2 , available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40099/abstract) for g/d T cells to produce IL-17. In these experiments, stimulation with S100A12 potentially generated a systemic JIAlike environment (Figure 1) . The possibility that endogenous TLR-4 ligands such as S100A12 or S100A8/A9 could promote the observed elevated IL-17 expression also under sterile inflammatory conditions is intriguing (28) (29) (30) .
In this context, it is striking that both in the systemic JIA mouse and in systemic JIA patients, IL-17 overexpression appears to be restricted to g/d T cells. In systemic JIA patients, this seemed to occur independently of clinical disease activity, although we cannot rule out an effect of disease duration on our observations ( Figure 3D and Table  1 ). Of note, g/d T cell overexpression of IL-17 was not as pronounced during active systemic JIA, although serum levels of IL-1b, IL-6, and S100A12 were highest during this disease phase ( Figure 3D ). Consistent with this, serum from systemic JIA patients with active clinical disease was able to promote IL-17 expression in healthy donor g/d T cells, as compared to sera from patients in remission or healthy controls ( Figure 5A ).
As (Figure 3C ) and others (22, 31, 32) , might in fact support the idea of the migration of human g/d T cells into inflamed tissues such as the synovium, where they drive local inflammation during active disease (22, 31, 32) . Recirculation of g/d T17 cells via peripheral blood and lymph is thought to spread and aggravate inflammation in multiple tissues (33, 34) . Similar to chronic stimulation with bisphosphonate resulting in the accumulation of IPP (35, 36) , decreased IFNg expression as induced by these peripheral cells during active systemic JIA ( Figure 3C ) may indicate exhaustion following their participation in tissue-borne inflammatory processes. Alternatively, as suggested by a study on psoriasis patients (37), a low frequency of, and reduced cytokine expression by, peripheral g/d T cells, particularly during active disease, reflects recruitment of a specific proinflammatory g/d T cell subset to drive the local inflammation. Upon disease inactivity, this again increases in the periphery due to recirculation or less migration into tissue (37) .
Apart from g/d T cells, it remains to be discussed why, under the test conditions aimed at activation rather than de novo differentiation of Th cell subsets (38) , the patients' Th17 cells did not reveal comparably increased IL-17 expression. Our data may point to a role of IL-23 in accounting for this divergence. IL-23 is strictly required for human Th17 cell differentiation and maintenance (39, 40) . However, in contrast to IL-1b and IL-6, serum levels of IL-23 were not elevated in systemic JIA, while the lowest concentrations were detected during active disease ( Figure  1 ). Furthermore, in vitro experiments indicated no changes in IL-23 levels, particularly following S100A12 or cytokine stimulations (Supplementary Figures 2C and F and 3C , available at http://onlinelibrary.wiley.com/doi/10.1002/art. 40099/abstract).
In contrast to IL-23 levels, systemic JIA patients had highly elevated levels of IL-18 ( Figure 1) (21,41) , while g/d TCR1, but not CD41, T cells from both healthy donors and systemic JIA patients expressed high levels of IL-18 receptor (Supplementary Figure 4A) . In our g/d T cell stimulation experiments, supplementing cocultures with both IL-1b and IL-18 further increased IL-17 expression by g/d T cells, which was most pronounced when combined with S100A12 ( Figure 5B ).
These data support the findings on murine cells reported earlier, which suggested that IL-18-induced g/d T cell IL-17 expression was mediated in part through IL-1 (42) . In fact, in our cocultures, the addition of IL-18 resulted in elevated IL-1b expression ( Supplementary Figure 3A) and significantly enhanced IPP-induced proliferation of g/d T cells from patients as well as healthy donors (Supplementary Figures 4B and C) . The latter may not necessarily happen at the systemic level, as we did observe g/d T cell expansion in whole blood, but may be restricted to tissue, as particularly macrophages (43) and keratinocytes (44) have been suggested to be major producers of IL-18.
Further indicating the IL-1 dependence of g/d T cell IL-17 expression, we observed this to be reduced in whole blood from patients treated with canakinumab (Figure 3E) . This seemed to occur irrespective of the patients' underlying disease activity. However, it has to be noted that these observations are based on rather small patient numbers and the groups were not normalized for median disease duration (4.5 years for anti-IL-1; 8 years for other treatments). More importantly, IL-17A released from isolated g/d T cells was significantly reduced in the presence of canakinumab, efficiently neutralizing free IL-1b (Supplementary Figure 2A , available at http://onlinelibrary. wiley.com/doi/10.1002/art.40099/abstract).
A critical role of IL-1b in g/d T cell IL-17 expression has also been demonstrated in mice developing IL-17-dependent spontaneous arthritis due to the lack of endogenous IL-1Ra (IL-1rn -/-mice) expression (45, 46) . Recently, arthritis development in IL-1rn -/-mice was found to depend on both g/d T cells and CD41 T cells.
IL-1rn
-/-g/d T cells demonstrated increased IL-1 receptor expression and thus enhanced sensitivity for IL-1. They served as the main source of IL-17 in inflamed joints but required CD41 T cells for tissue homing (47) .
In systemic JIA, the simultaneous decrease in peripheral IL-17/IFNg-expressing CD41 and g/d T cells, particularly during active disease ( Figures 1C and 2C) , may indicate a similar concerted action of these cells. Yet, further studies analyzing chemotaxis, phenotype, and function of T cells, especially in systemic JIA tissue, are required to prove this.
Apart from IL-1b, IL-6 serum levels were strongly elevated in systemic JIA (Figure 1) , and therapeutic IL-6R blockade is a highly effective treatment option (10) . IL-6 is another cytokine that is critically involved in the differentiation of IL-17-expressing T cells (48) . Yet, although IL-6 concentrations were strongly increased in cultures stimulated with either LPS or S100A12 (Supplementary Figures 2B and E and 3B, available at http://onlinelibrary.wiley. com/doi/10.1002/art.40099/abstract), IL-6 is thought to be dispensable for g/d T cell IL-17 expression (49, 50) . In fact, the results of our ex vivo and in vitro experiments do not support the idea that either therapeutic or experimental IL-6R blockade might affect IL-17 expression by g/d T cells.
In summary, it is conceivable that a "systemic JIA serum factor environment" characterized by high levels of IL-1b and IL-18, likely induced by overexpressed endogenous TLR-4 ligands such as S100 proteins, specifically primes g/d T cells for IL-17 overexpression (Supplementary Figure 5 ). This may be further promoted by low levels of T cell IFNg production, as IFNg-induced STAT-1 signaling has been shown to impair human IL-17 immunity (51). While significantly increased CD41IFNg1 cell frequencies have been observed in whole blood ( Figure 2C ) and PBMCs (13) from systemic JIA patients, we now report that these cells reveal decreased IFNg expression ( Figures 2C and 4C ). Although this is not readily apparent at the serum level (Figure 1) (8,21) , we observed decreased CXCL9 expression, indicating weak IFNg-signaling. CXCL10 serum levels were nonsignificantly elevated during active systemic JIA (Figure 1 ), although CXCL10 expression has been demonstrated to result from either IFNg or TLR-4 signaling (52), as for example, that triggered by S100A12. Along similar lines, gene expression profiles in monocytes from active systemic JIA patients (53) failed to demonstrate strong IFNg-induced transcriptional signatures, which can be suggestive of a limited in vivo exposure of cells to IFNg.
IL-1 blockade efficiently abrogated IL-17 overexpression by g/d T cells and contributed to the normalization of T cell IFNg expression. IFNg has been described as a potential master switch in systemic JIA. Aberrantly low levels can contribute to the progression of autoimmune arthritis, but IFNg overexpression may drive MAS as one of the most severe systemic JIA complications (54) . As decreased IFNg release has so far been attributed to defective NK cells in systemic JIA (55, 56) , investigating the mechanisms that contribute to low levels of IFNg expression on CD41 T cells may allow a deeper understanding of the complex pathophysiology of systemic JIA in the future.
